Skip to main content
. Author manuscript; available in PMC: 2012 Oct 11.
Published in final edited form as: J Immunother. 2010 Sep;33(7):697–705. doi: 10.1097/CJI.0b013e3181eb826d

FIGURE 4.

FIGURE 4

Tumor-specific CTL activity following i.t. immunotherapy with chitosan/IL-12. Splenocytes from mice that were cured of primary tumors following i.t. chitosan/IL-12 immunotherapy and also resisted tumor rechallenge were stimulated in vitro for one week and tested for CTL activity. (A) splenocytes were stimulated with irradiated MC32a cells and measured for CTL activity against MC32a targets (●) or EL-4 targets (○). (B) splenocytes were stimulated with 10 µg/mL CEA526-533 and measured for CTL activity against CEA526-533-pulsed EL-4 targets (■) or HIV gag390-398-pulsed EL-4 targets (□). (C) splenocytes were stimulated with 1 µg/mL p15E604-611 (gp70 peptide) and measured for CTL activity against p15E604-611-pulsed EL-4 targets (▲) or β-gal96-103-pulsed EL-4 targets (Δ). Each data point represents mean percent lysis ± SEM from 4 mice. * indicates P < 0.05 vs. controls.